Following The Politics of Breast Cancer webinar in May, we turned BCAction’s critical eye on the FDA and its drug approval process.
Breast cancer treatments should be both the most effective and the least toxic possible. The standards used by the FDA for the approval of new breast cancer therapies and devices should ensure this outcome. However, pharmaceutical companies, the government and cancer patients don’t share the same interests. This webinar will talk about whom the power players at the FDA are, BCAction’s take on the related conflicts of interests, and the history of the approval process.